ArticleJournal of experimental & clinical cancer research : CR2026
The PPTC7/BNIP3/NIX axis induces cGAS/STING-mediated senescence and augments CAR-T efficacy by repressing tumor-intrinsic mitophagy.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In multiple myeloma (MM), resistance to B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) treatment continues to limit therapeutic benefit, whereas the tumor-intrinsic factors governing sensitivity to CAR-T remain poorly understood. Here, integrating public single-cell RNA-seq data with transcriptomic profiling of MM cells before and after CAR-T exposure, we identified the mitochondrial protein PPTC7 as a key modulator linking tumor mitophagy to innate immune activation and CAR-T efficacy. Mechanistically, PPTC7 acted as a negative regulator of tumor-intrinsic mitophagy by promoting SCF^FBXL4-dependent ubiquitination and proteasomal degradation of the mitophagy receptors BNIP3 and NIX, thereby suppressing mitophagic flux. Consistent with this, PPTC7 overexpression inhibited mitophagy, caused mitochondrial dysfunction, and increased cytosolic leakage of mitochondrial DNA (mtDNA), whereas PPTC7 knockdown stabilized BNIP3/NIX, enhanced mitophagy, and reduced cytosolic mtDNA. The accumulated cytosolic mtDNA consequent to mitophagy suppression activated the cGAS/STING pathway, induced a senescence-associated secretory phenotype, and remodeled the inflammatory tumor microenvironment. Functionally, PPTC7-mediated mitophagy repression markedly enhanced CAR-T cytotoxicity in vitro and promoted CAR-T infiltration and tumor control in vivo. Rescue experiments further supported this axis: restoring mitophagy via NIX attenuated mtDNA leakage and dampened cGAS/STING signaling and CAR-T activity, whereas re-activating cGAS reinstated inflammatory signaling and CAR-T effector function. Collectively, our findings define a tumor-intrinsic PPTC7-BNIP3/NIX-mtDNA-cGAS/STING circuit in which suppression of mitophagy increases tumor immunogenicity and sensitizes MM to CAR-T therapy, highlighting PPTC7 as a potential immune-sensitizing target to overcome CAR-T resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.